2Flo Ventures
2Flo Ventures is a Chicago-based early-stage venture capital firm and startup studio that invests in and builds healthcare and life sciences companies advancing health equity, supported by a 40+ advisor network and nine portfolio companies.
- Company typePrivate
- Founded2021
- HeadquartersChicago, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What 2Flo Ventures does
2Flo Ventures is a Chicago-based early-stage venture capital firm and startup studio founded in 2021 that invests in healthcare and life sciences companies addressing large unmet medical needs and health disparities. The firm operates a dual model, deploying equity capital into portfolio companies while also providing hands-on operational support across regulatory, clinical, commercial, and financial domains through a 40+ advisor network and a five-person core team led by Managing Partner Paul Burton, JD, MBA. Its portfolio of nine companies spans biotechnology (Vivacelle Bio's phospholipid nanoparticle VBI-S for septic shock, Temprian Therapeutics' HSP70i immunotherapy for autoimmune disease, Akan Biosciences' StroMel SVF stem cell therapy), medical devices, and digital health (CancerIQ's EHR-integrated precision health platform used at 180+ locations, 4D Healthware's enhanced telehealth platform, KeyCare built natively inside Epic). Portfolio companies have collectively raised over $85 million across rounds including a $14M CancerIQ Series B co-led by Merck GHI and Amgen Ventures, a $5.3M US Navy award to Vivacelle Bio, and prior backing from HealthX Ventures, McKesson Ventures, and OSF Ventures.
The firm's business model combines traditional VC economics—management fees on managed capital and carried interest on exits—with startup studio economics in which operational support is exchanged for equity at company inception. Deal sourcing runs through a 'Pitch to Us' Airtable form, warm introductions via the advisor network, and a recurring event ecosystem including the annual Health Equity Investing Symposium (2023-2025, with 2026 announced), the Health Equity Pitch Competition (launched 2025), the Martha's Vineyard Summit, and the SF JPM Reception co-hosted with Women of Color in Pharma. Strategic brand-building activity includes an op-ed in Fierce Healthcare, conference presence at BIO International Convention and JP Morgan Healthcare Conference, and recognition including Temprian Therapeutics as a Nature Spinoff Prize 2020 finalist and the in-house Health Equity Titan of the Year Award presented to Dr. Aletha Maybank at the 2025 Women's Health Edition Symposium. Customers, in the LP and founder sense, are institutional and strategic investors, early-stage healthcare and life sciences entrepreneurs, and health systems adopting portfolio technologies.
2Flo Ventures firmographics
Firmographics- Name
- 2Flo Ventures
- Legal name
- 2Flo Ventures
- Website
- https://2floventures.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- 2Flo Ventures is a Chicago-based early-stage venture capital firm and startup studio that invests in and builds healthcare and life sciences companies advancing health equity, supported by a 40+ advisor network and nine portfolio companies.
- Ownership category
- akta.pro rank
2Flo Ventures industry classification
Industry- Product category
- Healthcare Venture Capital
- NAICS
- Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
Keywords
Where 2Flo Ventures is headquartered
LocationHeadquarters
- HQ city
- Chicago
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
2Flo Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Marketing or Sales, Operations
Revenue model
- Venture Capital Fund Management: 2Flo Ventures generates returns through traditional VC mechanisms: management fees on managed funds, carried interest (performance fees) on successful portfolio company exits, and co-investment rights. The firm builds and invests in early-stage healthcare companies with the goal of generating meaningful returns for stakeholders while advancing health equity.
- Startup Studio Services: As a startup studio, 2Flo Ventures provides operational support, strategic guidance, regulatory expertise, commercial strategy, and network access to portfolio companies. In return, the firm builds equity stakes in portfolio companies. The studio model allows 2Flo to shape companies from inception and capture greater value at exit.
- Portfolio Company Capital Raising: 2Flo Ventures portfolio companies raise independent funding rounds from institutional investors and strategic partners. Examples: CancerIQ raised $4.8M Series A (led by HealthX Ventures) and $14M Series B (co-led by Merck GHI and Amgen Ventures). Vivacelle Bio received a $5.3M award from the US Navy. These rounds generate dilution for 2Flo but increase portfolio valuation.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Venture Investment — negotiated per company |
| Outcome Based/ Performance | Annual | Health Equity Pitch Competition — prize structure |
Go-to-market motion3 records
Distribution channels4 records
Marketing channels7 records
2Flo Ventures product offering
Product offeringCore offering
2Flo Ventures is a Chicago-based early-stage venture capital firm and startup studio that invests in and helps build healthcare and life sciences companies addressing large unmet medical needs and advancing health equity. The firm deploys equity capital into nine portfolio companies spanning biotechnology, medical devices, and digital health, while providing hands-on operational support, regulatory expertise, commercial strategy, and access to a 40+ advisor network. It also operates a proprietary event ecosystem (annual Health Equity Investing Symposium, Health Equity Pitch Competition, Martha's Vineyard Summit, and SF JPM Reception) to source deals and cultivate a community of founders and investors.
Differentiator
Problem solved
Functional benefit
Products and services
- Venture Capital Investment Early-stage equity capital investment in healthcare and life sciences startups addressing large unmet medical needs and advancing health equity. Investment amounts and ownership stakes are negotiated per company; supported by an inbound 'Pitch to Us' Airtable funnel, warm advisor introductions, and event-driven deal sourcing. Portfolio includes Vivacelle Bio, Temprian Therapeutics, Delphian Therapeutics, ResQ Pharma, KeyCare, CancerIQ, Temprian Oncology, Akan Biosciences, and 4D Healthware.
- Startup Studio Services Hands-on operational support provided to portfolio companies from inception, including regulatory expertise, commercial strategy, financial guidance, and access to a 40+ advisor network spanning venture partners, senior advisors, strategic advisors, regulatory advisors, commercial advisors, healthcare advisors, and finance advisors. In return, the studio builds equity stakes and shapes companies from inception.
- Health Equity Pitch Competition Annual pitch competition for idea-stage and early-stage founders with novel solutions advancing health equity; industry-agnostic with focus on the specific health equity idea. Awards cash prizes and in-kind donations from Chicago ecosystem leaders across legal, finance, pitch coaching, strategy, marketing, regulatory, business development, and design domains (1st: $1,000 cash + $5,000 in-kind; 2nd: $600 cash + $2,000 in-kind; 3rd: $400 + $1,000 in-kind). Applications via Google Forms; finalists present in person in Chicago.
- Health Equity Investing Symposium Flagship annual one-day forum bringing together investors, founders, healthcare leaders, and policymakers; features panel discussions, company showcases, Venture Engine presentations, and the Health Equity Titan of the Year award. Sourced and curated by 2Flo Ventures, with themed editions such as the 2025 Women's Health Edition. Functions as a deal-sourcing and community-building event.
Quantifiable outcome
- Portfolio companies have collectively raised over $85 million and employ over 100 people across 9 companies
- +3 more outcomes
Companies that use 2Flo Ventures
Customer profileNamed customers4 records
Segments3 records
Ideal customer profiles3 records
2Flo Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration6 records
AI capability2 records
Feature5 records
2Flo Ventures partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered minor and core.
- Rubix LSminorRubix LS sponsored the 2025 Health Equity Investing Symposium: Women's Health Edition, with Remarks delivered by Reginald Swift of Rubix LS.
- Cushman & WakefieldminorCushman & Wakefield generously provides event space in Chicago to host 2Flo Ventures' Health Equity Pitch Competition events. This enables the firm to hold its annual pitch competition in person at a Chicago venue, supporting the firm's community-building and deal-sourcing mission.
- Sepsis Alliancecore2Flo Ventures partnered with Sepsis Alliance for the 2024 Health Equity Investing Symposium. Sepsis Alliance leads efforts to save lives and reduce suffering from infections and sepsis through public education, healthcare professional training, regulatory advocacy, and research collaboration. All proceeds from the 2024 symposium were donated to Sepsis Alliance.
- Latham & WatkinsminorLatham & Watkins served as a sponsor of the 2024 Health Equity Investing Symposium. Sponsorship supports the event's community-building and thought leadership objectives.
- CooleyminorCooley served as a sponsor of the 2024 Health Equity Investing Symposium and co-hosted the SF JPM Reception with 2Flo Ventures and WOCIP.
- Illinois Science and Technology Coalition (ISTC)minorISTC, through its Venture Engine program, co-sponsored the 2024 Health Equity Investing Symposium and hosted the Venture Engine Showcase featuring early-stage life science and biotech companies.
- CBREminorCBRE served as a sponsor of the 2024 Health Equity Investing Symposium.
- Loop CapitalminorLoop Capital served as a sponsor of the 2024 Health Equity Investing Symposium.
- Michael BestminorMichael Best served as a sponsor of the 2024 Health Equity Investing Symposium.
- Women of Color in Pharma (WOCIP)core2Flo Ventures co-hosts the annual SF JPM Reception with Women of Color in Pharma (WOCIP) during JP Morgan Healthcare Conference week in San Francisco. The event brings together healthcare leaders, investors, and innovators for networking and discussion. 2Flo Managing Partner Charlotte Jones-Burton founded and presides over WOCIP, creating a strong co-founding relationship.
- World Business ChicagominorWorld Business Chicago, in partnership with Mayor Brandon Johnson, announced the Chicago Venture Summit: Future of Health for October 2026. 2Flo Ventures operates within Chicago's healthcare innovation ecosystem and participates in regional economic development initiatives promoting Chicagoland's healthcare sector.
Scale indicators8 records
Recent moves6 records
Expansion highlights5 records
2Flo Ventures competitors and assessment
Company assessmentDirect peers
- Third Rock Ventures: Biotech-focused venture firm that builds and launches healthcare companies from inception. Direct peer in the startup-studio / company-creation model for life sciences, although operating at much larger scale and exclusively in therapeutics.
- HealthX Ventures: Wisconsin-based digital health-focused early-stage VC. Direct peer — HealthX led CancerIQ's Series A and participated in its Series B alongside 2Flo, and shares a digital-health/health-equity investment thesis targeting the Midwest healthcare ecosystem.
- Flare Capital Partners: Boston-based early-stage healthcare technology VC investing across digital health, health IT, and care delivery. Direct peer in the early-stage, healthcare-focused VC category with similar check sizes and similar thesis on transforming care delivery.
- Civilization Ventures: Early-stage health tech and digital health VC with a thesis aligned with democratizing healthcare access. Direct peer in mission-aligned, early-stage healthcare venture investing.
- Maverick Ventures: Early-stage venture firm with a healthcare and technology focus, often writing first checks alongside operators. Direct peer given similar stage, sector breadth, and willingness to syndicate with strategic healthcare investors.
Broad incumbents
- ARCH Venture Partners: Large, established venture firm focused on early-stage life sciences and physical sciences companies. Broad incumbent with overlapping sector exposure (biotech/therapeutics) but materially larger fund sizes and broader portfolio than 2Flo's boutique health-equity studio.
- Flagship Pioneering: Flagship is a bioplatform innovation company that conceives, creates, and grows biotech companies from internal hypotheses — the gold-standard biotech startup studio. Broad incumbent analogue for 2Flo's studio model, though operating at vastly larger scale.
- Andreessen Horowitz (a16z) Bio + Health Fund: Large venture franchise with a dedicated Bio + Health fund investing across digital health, biotech, and care delivery. Broad incumbent that competes for the same healthcare founder pool at significantly larger check sizes.
Emerging players
- Kapor Capital: Impact-focused venture firm investing in early-stage companies addressing gaps for underrepresented communities, with a notable health-equity lens. Emerging player with overlapping health-equity impact thesis and similar commitment to underrepresented founders.
- Rock Health: Digital health venture fund and advisory platform supporting early-stage companies and convening the digital health ecosystem. Emerging player with overlapping digital-health focus and similar community/event-driven approach to deal sourcing.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks2 records
Key highlights6 records
Customer concentration
2Flo Ventures social profiles
Digital presence2Flo Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
2Flo Ventures leadership team
Management profileNumber of profiles
Profiles1 record
2Flo Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
2Flo Ventures M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 2Flo Ventures
What does 2Flo Ventures do?
2Flo Ventures is a Chicago-based early-stage venture capital firm and startup studio that invests in and helps build healthcare and life sciences companies addressing large unmet medical needs and advancing health equity. The firm deploys equity capital into nine portfolio companies spanning biotechnology, medical devices, and digital health, while providing hands-on operational support, regulatory expertise, commercial strategy, and access to a 40+ advisor network. It also operates a proprietary event ecosystem (annual Health Equity Investing Symposium, Health Equity Pitch Competition, Martha's Vineyard Summit, and SF JPM Reception) to source deals and cultivate a community of founders and investors.
Is 2Flo Ventures a public or private company?
2Flo Ventures is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was 2Flo Ventures founded?
2Flo Ventures was founded in 2021. It employs 1 to 10 people.
Where is 2Flo Ventures based?
2Flo Ventures is headquartered in Chicago, United States, in the North America region.
How does 2Flo Ventures make money?
Three revenue lines are on record. Venture Capital Fund Management is the primary driver. The others are startup Studio Services and portfolio Company Capital Raising.
Who are 2Flo Ventures's main competitors?
Direct peers on record are Third Rock Ventures, HealthX Ventures, Flare Capital Partners, Civilization Ventures and Maverick Ventures. Broad incumbents are ARCH Venture Partners, Flagship Pioneering and Andreessen Horowitz (a16z) Bio + Health Fund. Emerging players are Kapor Capital and Rock Health.
Does 2Flo Ventures have an API?
No public API is recorded for 2Flo Ventures.
What industry is 2Flo Ventures in?
2Flo Ventures's product category is Healthcare Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 523940 and its SIC code is 6282.